You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MET exon 14 skipping

Showing 1 - 25 of 7,747
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • East Hanover, New Jersey
    18 Novartis Investigative Sites in the US
Dec 29, 2022

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)

    Recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer
    • San Francisco, California
      University of California San Francisco
    Aug 15, 2022

    Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

    Recruiting
    • Non-Small Cell Lung Carcinoma
    • Capmatinib 150 mg
    • Capmatinib 200 mg
    • Guwahati, Assam, India
    • +7 more
    Dec 19, 2022

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

    Not yet recruiting
    • Recurrent Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer AJCC v8
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 7, 2023

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Advanced NSCLC Trial (CT053PTSA)

    Not yet recruiting
    • Advanced NSCLC
    • (no location specified)
    Jul 29, 2021

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    Carcinoma, Non-Small Cell Lung, NSCLC, Non-Small-Cell Lung Carcinoma Trial (Capmatinib)

    Available
    • Carcinoma, Non-Small Cell Lung
    • +3 more
    • (no location specified)
    Aug 31, 2021

    NSCLC Trial in United States (capmatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • La Jolla, California
    • +7 more
    Oct 5, 2022

    Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))

    Completed
    Has Results
    • Malignant Non-small Cell Neoplasm of Lung Stage IV
    • Capmatinib (INC280)
    • Boston, Massachusetts
      Massachusetts General Hospital
    Mar 11, 2022

    NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center of Sun-Yat Sen University
    Sep 19, 2023

    NSCLC Trial in Guangzhou (PLB1001)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Aug 15, 2023

    Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification Trial in Korea, Republic of (Tepotinib)

    Recruiting
    • Solid Tumor
    • +2 more
    • Hwasun, Chonnam, Korea, Republic of
    • +21 more
    Nov 30, 2020

    Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

    Not yet recruiting
    • Advanced Cancer
    • Non Small Cell Lung Cancer
    • (no location specified)
    Mar 28, 2023

    Gastric Cancer, Gastroesophageal-junction Cancer Trial in Gyeonggi-do (Tepotinib plus paclitaxel)

    Recruiting
    • Gastric Cancer
    • Gastroesophageal-junction Cancer
    • Tepotinib plus paclitaxel
    • Gyeonggi-do, Korea, Republic of
      Hallym University Medical Center
    Jun 29, 2022

    Special Drug Use-results Surveillance of Tabrecta Tablets

    Recruiting
    • Non-small Cell Lung Cancer
    • Tabrecta tablets
    • Nagoya, Aichi, Japan
    • +44 more
    Aug 1, 2022

    Solid Tumor Trial in El Segundo (AMG 337)

    Withdrawn
    • Solid Tumor
    • AMG 337
    • El Segundo, California
      Chan Soon-Shiong Institute for Medicine
    Aug 23, 2019

    NSCLC, Solid Tumor Trial in Boston (Merestinib)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Solid Tumor
    • Boston, Massachusetts
    • +1 more
    Jan 26, 2022

    NSCLC Trial in Worldwide (Capmatinib, Amivantamab)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Orange, California
    • +40 more
    Aug 3, 2022

    Advanced (Stage IIIB/IV) NSCLC (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Trial in Worldwide

    Active, not recruiting
    • Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
    • Duarte, California
    • +140 more
    Jun 7, 2022

    NSCLC Metastatic Trial in Shanghai (Savolitinib)

    Recruiting
    • Non-small Cell Lung Cancer Metastatic
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Aug 30, 2021

    Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

    Recruiting
    • Lung Neoplasms
    • +3 more
    • Observation
    • Shanghai, China
      Shanghai Chest Hospital
    Mar 14, 2022

    NSCLC Trial in Houston (Amivantamab, Tepotinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 9, 2023

    Tabrecta® (Capmatinib) in South Korea

    Not yet recruiting
    • Non-Small-Cell Lung Carcinoma
    • Capmatinib
    • (no location specified)
    Jan 19, 2023